Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma

Campbell, BA; Minson, A; Brown, RJ; Chin, CK; Wirth, A; Hofman, MS; MacManus, M; Seymour, JF; Ritchie, D; Dickinson, M

Author(s): Campbell, BA; Minson, A; Brown, RJ; Chin, CK; Wirth, A; Hofman, MS; MacManus, M; Seymour, JF; Ritchie, D; Dickinson, M;
Details: Publication Year 2026-04,Volume 67,Issue #5,Page 1100-1108
Journal Title: Leukemia & Lymphoma
Publication Type: Research article
Abstract: Following salvage chemotherapy (SC) and autologous stem-cell transplantation (ASCT), 30-60% of patients with relapsed/refractory Hodgkin lymphoma (r/rHL) experience disease relapse. Appropriate patient selection for consolidation radiotherapy (cRT) may improve outcomes. Positron-emission tomography (PET) is a powerful prognostic tool, with potential utility in PET-directed therapy. Predictive roles of post-SC metabolic and structural response assessments, and prognostic impact of peri-transplant cRT, were retrospectively evaluated in r/rHL patients from two tertiary hospitals, median follow-up >5 years. Five-year progression-free survival (PFS) was 65% (95%CI 55-74%). Metabolic response post-SC significantly predicted PFS. For patients with complete metabolic response (CMR) post-SC, structural residuum ≥2 cm suggested inferior PFS. Potential PFS advantages from cRT were observed in all subgroups with limited-stage r/rHL, regardless of response post-SC. Peri-transplant cRT may abrogate the negative predictive value of non-CMR or residual masses ≥2 cm in CMR post-SC. In advanced-stage r/rHL, post-SC non-CMR predicted for poor outcomes, warranting prioritization of alternative salvage strategies.
Publisher: Taylor & Francis
Keywords: Humans; *Hodgkin Disease/therapy/mortality/pathology/radiotherapy/diagnosis; Male; Female; Adult; Middle Aged; Salvage Therapy; Retrospective Studies; Young Adult; *Hematopoietic Stem Cell Transplantation; Positron-Emission Tomography; Prognosis; *Neoplasm Recurrence, Local/therapy; Aged; Adolescent; Treatment Outcome; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Drug Resistance, Neoplasm; Transplantation, Autologous; Combined Modality Therapy; Neoplasm Staging; Follow-Up Studies; Neoplasia; clinical results; lymphoma and Hodgkin disease; marrow and stem cell transplantation; prognostication; radiation
Department(s): Radiation Oncology; Haematology; Cancer Imaging
Publisher's Version: https://doi.org/10.1080/10428194.2026.2631102
Open Access at Publisher's Site: https://doi.org/10.1080/10428194.2026.2631102
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-05-12 05:40:23

Last Modified: 2026-05-12 05:40:39